ASCO Annual Meeting
Sarah Donahue Highlights Destiny-Breast04 Trial Takeaways for Patients With HR+, HER2-Low Metastatic Breast Cancer
August 01, 2022
Podcast
Sarah Donahue, MPH, NP, AOCNP, explains the trial design of the pivotal DESTINY-Breast04 trial and discusses how the promising performance of trastuzumab deruxtecan might impact patients with unresectable or metastatic HER2-low breast cancer.
Ripretinib Exhibits Better Tolerability Profile Vs Sunitinib in Advanced GIST Tumors
July 27, 2022
Article
An analysis of patient-reported outcomes from the phase 3, INTRIGUE trial (NCT03673501) showed that ripretinib had a more tolerable safety profile than sunitinib in treating patients with advanced GIST tumors.
Uniform Baseline Measurements Are Crucial in Improving Standard of Supportive Care
July 26, 2022
Article
Lidia Schapira, MD, FASCO, discusses the importance of rigorous baseline measurement in improving the assessment and management of distressful cancer symptoms.
Axi-cel Linked To Longer Quality Time Without Toxicity in Patients With R/R LBCL
July 22, 2022
Article
A quality time without symptoms of toxicities analysis of the pivotal ZUMA-7 trial found that patients with relapsed or refractory large B-cell lymphoma experienced longer time without toxicity with axicabtagene ciloleucel than with standard of care.
Extended Follow-Up Shows Durable Outcomes, No New Safety Signals With Brexucabtagene Autoleucel in R/R B-ALL
July 19, 2022
Article
Brexucabtagene autoleucel, a CAR T-cell therapy approved in 2021 for relapsed or refractory B-cell acute lymphoblastic leukemia, showed efficacious results and promising safety data at 2-year follow-up.
Frontline Ribociclib-Related Quality of Life Favorable to Abemaciclib in HR+/HER2- Advanced Breast Cancer
July 15, 2022
Article
Ribociclib was associated with significantly favorable symptom-related quality of life scores compared with abemaciclib among women with hormone receptor–positive, HER2-negative advanced breast cancer.
Bevacizumab With Olaparib Extends Time to Toxicity in Patients With Newly Diagnosed Ovarian Cancer
July 14, 2022
Article
Patients receiving bevacizumab plus olaparib to treat newly diagnosed ovarian cancer experienced significantly longer time without signs of toxicity compared with placebo.
7.5-Year Follow-Up Affirms Nivolumab’s Superiority Over Ipilimumab in Advanced Melanoma
July 13, 2022
Article
Nivolumab, whether in combination with ipilimumab or as a monotherapy, was associated with improved overall survival, progression-free survival, and melanoma-specific survival, compared with ipilimumab in advanced melanoma.
Geriatric Assessment Rates Improve With Nurse Navigator Intervention
July 05, 2022
Article
Nurse navigators may play a key role in mitigating toxicities from chemotherapy and perform geriatric assessments for patients treated at hematology/oncology clinics.
Burbage Provides Nursing Perspective on 2022 ASCO Meeting
July 01, 2022
Article
Darcy Burbage, DNP, RN, AOCN, CBCN, discusses the top takeaways from the 2022 ASCO Annual Meeting for oncology nurses.